Medina-Dávalos R, Saavedra-Herrera S, González-González C

Language: Spanish
References: 11
Page: 114-117
PDF size: 350.50 Kb.

ABSTRACT

Objective: Describes perceptions relatives of patients with severe and persistent mental disorder about use antipsychotic long-acting injections (AILD), also described the infl uence of socio-demographic variables in the perception of AILD use in patients with severe and persistent mental disorder. Methods: A survey was applied to a hundred family members of individuals with severe and persistent mental disorder, in the Long Stay CAISAME, the same was collected with a tool made on purpose, once obtained the survey, proceeded to combine a database and given treatment statistical. Results: Hundred families were evaluated, 66% female and 34% male. Th e perception during the acute phase of the disease was; 71% considered the most appropriate injection and 72% of the families prefer long-acting injectable for long-term management of their relatives. Conclusion: Th e study shows that nearly half of the families unknow the AILD before the interview. We can infer that psychiatrists do not prescribe it as fi rst choice and perhaps relegate chronic patients with multiple readmissions and diffi cult to control.

REFERENCES

1. AMERICAN PSYCHIATRIC ASSOCIATION: Manual diagnóstico y estadístico de los trastornos mentales (DSM IV TR), cuarta edición revisada, Barcelona, Masson, 2002.

2. D.A.W. Johnson: “Historical perspective on antipsychotic longacting injections”. The British Journal of Psychiatric 2009; 195: 7-12.

3. Farzini I, MS, Dankert M, Siegel SJ: “Patient and family attitudes toward Schizophrenia Treatment”. Current Psychiatric Reports 2004; 6: 88-283.

4. Flores-Reynoso S, Medina-Dávalos R, Robles-García R, Páez-Agraz F: “Estigma y apego al tratamiento psiquiátrico en los trastornos mentales severos y persistentes”. Rev Latinoam Psiquiatría 2012; 11(3):82-89.

5. Fleischhacker W W: “Second-generation antipsychotic long-acting injections: systematic review.” Th e British Journal 2009, 195,s29-s36. doi: 10.1192/bjp.195.52.s29.

6. Gray R, Spilling R, Burgess D, Newey T, : “Antipsychotic longacting injectiosn in clinical practice:medication management and patient chice”. Th e British Journal 2009; 195, s51-s56. doi: 10.1192/ bjp. 195.52. s51.

7. Haddad PM, Taylor M, Niaz OS: “First –generation antipsychotic long-acting injections v. Oral antipsychotic in schizofrenia: systenatic review of randomised controlled trials and observational studies”. Th e British Journal 2009; 195, s20-s28. doi: 10.1192/ bjp.195.52. s20

8. Kane JM, Garcia-Ribera C: “Clinical guideline recomendations for antipsychotic long-acting injections”. Th e British Journal 2009; 195, s63-s67. doi: 10.1192/bjp.195.52.s63.

9. Lieberman, Jeff rey A., Stroup, T. Scott, McEvoy, Joseph P., Swartz, Marvin S., Rosenheck, Robert A., Perkins, Diana O., Keefe, Richard S.E., Davis, Sonia M., Davis, Clarence E., Levowitz, Barry D., Severe Joanne, Hsiao, John K: Eff ectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia 2005; 353:1209-23.

10. Pantel M, Taylor M, David A: “Antipsychotic long-acting injections mind the gap”. Th e British Journal of Psychiatric 2009; 195: 1-4.

11. Waddell L, Taylor M: “Attitudes of patients and mental health staff to antipsychotic long-acting injectios: systematic review”. The British Journal of Psychiatric 2009; 195: 43-50.